Ian Michael Estepan
Known title: Chief Financial OfficerCIK: 0001836254
Associated companies
Transaction History
| SRPT | ▼ Sell | Tax Withholding | 24,799 | $551K | 9/4/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 1,097 | $19K | 3/11/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 1,036 | $18K | 3/9/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 583 | $10K | 3/9/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 3,301 | $53K | 3/2/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 875 | $14K | 3/2/2026 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 8,125 | — | 3/1/2026 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 2,069 | $28K | 2/26/2026 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 5,381 | $74K | 2/26/2026 | View on chart |
| SRPT | ▼ Sell | Open Market | 13,187 | $294K | 12/16/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 50,000 | $0 | 9/3/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 93,875 | $0 | 9/3/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 1,051 | $105K | 3/10/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 2,890 | $289K | 3/10/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 8,276 | — | 3/10/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 585 | $61K | 3/7/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 9,094 | $943K | 3/7/2025 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 5,500 | — | 3/7/2025 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 17,500 | — | 3/6/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 1,370 | $139K | 3/4/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 557 | $58K | 3/3/2025 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 1,533 | $18K | 1/29/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 2,613 | $307K | 1/29/2025 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 14,267 | $171K | 1/29/2025 | View on chart |
| SRPT | ▼ Sell | Gift | 250 | $0 | 12/27/2024 | View on chart |
| SRPT | ▼ Sell | Open Market | 5,985 | $822K | 8/30/2024 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 2,483 | $409K | 6/24/2024 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 6,250 | — | 6/21/2024 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 1,035 | $127K | 3/8/2024 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 526 | $63K | 3/7/2024 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 1,389 | $174K | 3/4/2024 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 365 | $46K | 3/1/2024 | View on chart |
| SRPT | ▼ Sell | Open Market | 1,200 | $154K | 3/1/2024 | View on chart |
| SRPT | ▲ Buy | Grant | 6,000 | $0 | 3/1/2024 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 744 | $114K | 3/8/2023 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 1,370 | $215K | 3/6/2023 | View on chart |
| SRPT | ▲ Buy | Grant | 4,500 | $0 | 3/6/2023 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 378 | $56K | 3/1/2023 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 398 | $32K | 3/7/2022 | View on chart |
| SRPT | ▲ Buy | Grant | 8,000 | $0 | 3/7/2022 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 1,308 | $104K | 3/4/2022 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 376 | $28K | 3/1/2022 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 1,623 | $127K | 9/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Sarepta settles patent dispute with REGENXBIO for $39M
Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.
Sarepta settles patent dispute with REGENXBIO for $39M. Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.